← Leaderboards
Robert B. Jenkins
Mayo Clinic Coll Of Medicine, Rochester
$6,438,057
Attributed
$6,680,458
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $804.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,802,450 · 12
By mechanism
P01$8,121,992 · 4
R01$4,222,713 · 3
P30$1,419,742 · 2
RC1$983,862 · 1
U01$54,141 · 1
P50$0 · 1
Top collaborators
- Jeanette E Eckel Passow1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Daniel J. Schaid$10,676,578
- Iftikhar J Kullo$21,946,679
- Lewis R Roberts$8,981,499
- Stephen J Russell$9,318,537
Others in their field
Top investigators on “Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$49,046,612
- Melissa L Bondy · Stanford University$36,047,564
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
GliomaNeoplasm /Cancer GeneticsGeneticTumorGenetic MarkersBiomedical FacilityFluorescent In Situ HybridizationCytogeneticsPolymerase Chain ReactionMapsSpecimenGenesNeoplastic ProcessCellsCell TypeCell LineVariantMutationGenome Wide Association StudyGenomicsMalignant NeoplasmsNeoplastic TransformationComplementary DnaPathogenesis
Grant awards (49)
Using germline and somatic genetics to elucidate glioma risk and improve patient outcomes$484,803
R01 · FY2025 · CA
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS$604,499
R01 · FY2022 · CA · contact PI
UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS$200,000
R01 · FY2022 · CA · contact PI
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS$629,677
R01 · FY2021 · CA · contact PI
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS$640,142
R01 · FY2020 · CA · contact PI
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS$637,580
R01 · FY2019 · CA · contact PI
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS$633,992
R01 · FY2018 · CA · contact PI
Cytogenetics$92,053
P30 · FY2013 · CA · contact PI
Cytogenetics$160,779
P30 · FY2012 · CA · contact PI
Cytogenetics$95,164
P30 · FY2011 · CA · contact PI
Identification of 9p and 20q Germline Alterations in Glioblastoma Pathogenesis$486,065
RC1 · FY2010 · NS · contact PI
Cytogenetics$100,867
P30 · FY2010 · CA · contact PI
Identification of 9p and 20q Germline Alterations in Glioblastoma Pathogenesis$497,797
RC1 · FY2009 · NS · contact PI
Cytogenetics$99,854
P30 · FY2009 · CA · contact PI
CORE--CYTOGENETICS$136,015
P30 · FY2008 · CA · contact PI
CORE--CYTOGENETICS$134,449
P30 · FY2007 · CA · contact PI
CORE--CYTOGENETICS$72,850
P30 · FY2006 · CA · contact PI
CORE--CYTOGENETICS$70,920
P30 · FY2005 · CA
Molecular Markers of Glioma Initiation and Progression$1,991,288
P01 · FY2004 · CA
Molecular Markers of Glioma Initiation and Progression$129,818
P01 · FY2004 · CA
CORE--CYTOGENETICS$83,872
P30 · FY2004 · CA
Molecular Markers of Glioma Initiation and Progression$1,939,449
P01 · FY2003 · CA
Molecular Markers of Glioma Initiation and Progression$126,453
P01 · FY2003 · CA
Molecular Markers of Glioma Initiation and Progression$1,878,726
P01 · FY2002 · CA
Molecular Markers of Glioma Initiation and Progression$123,187
P01 · FY2002 · CA
CORE--CYTOGENETICS$72,259
P30 · FY2002 · CA
8Q24 REGION ASSOCIATED WITH PROSTATE CANCER PROGRESSION$0
P50 · FY2002 · CA
CORE--MOLECULAR MARKERS$0
P01 · FY2002 · CA
CORE--MOLECULAR MARKERS$0
P01 · FY2002 · CA
BIOLOGIC AND CLINICAL STUDIES OF 19Q AND 1P IN GLIOMAS$0
P01 · FY2002 · CA
BIOLOGIC AND CLINICAL STUDIES OF 19Q AND 1P IN GLIOMAS$0
P01 · FY2002 · CA
CORE--STUDY DESIGN AND DATA ANALYSIS$0
P01 · FY2002 · CA
CORE--STUDY DESIGN AND DATA ANALYSIS$0
P01 · FY2002 · CA
Molecular Markers of Glioma Initiation and Progression$1,839,107
P01 · FY2001 · CA
CORE--CYTOGENETICS$228,401
P30 · FY2001 · CA
GENETIC AND BIOLOGIC STUDIES OF 1P AND 19Q IN GLIOMAS$99,572
R01 · FY2001 · CA
Molecular Markers of Glioma Initiation and Progression$93,964
P01 · FY2001 · CA
CORE--CYTOGENETICS$72,259
P30 · FY2001 · CA
CORE--STUDY DESIGN AND DATA ANALYSIS$0
P01 · FY2001 · CA
CORE--STUDY DESIGN AND DATA ANALYSIS$0
P01 · FY2001 · CA
CORE--MOLECULAR MARKERS$0
P01 · FY2001 · CA
CORE--MOLECULAR MARKERS$0
P01 · FY2001 · CA
BIOLOGIC AND CLINICAL STUDIES OF 19Q AND 1P IN GLIOMAS$0
P01 · FY2001 · CA
BIOLOGIC AND CLINICAL STUDIES OF 19Q AND 1P IN GLIOMAS$0
P01 · FY2001 · CA
8Q24 REGION ASSOCIATED WITH PROSTATE CANCER PROGRESSION$0
P50 · FY2001 · CA
GENETIC AND BIOLOGIC STUDIES OF 1P AND 19Q IN GLIOMAS$292,448
R01 · FY2000 · CA
MOLECULAR PATHOLOGY OF GLIOMAS$54,141
U01 · FY2000 · CA
CORE--CYTOGENETICS$0
P30 · FY2000 · CA
CORE--CYTOGENETICS$0
P30 · FY2000 · CA